Please assess the completion status of the following clinical trial:

Trial Title: Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed liver metastases secondary to uveal melanoma~  * Surgically incurable or unresectable disease~* No detectable extrahepatic metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~Hepatic~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* ALT and AST \< 5 times ULN~* Alkaline phosphatase \< 5 times ULN~* Gamma-glutamyltransferase \< 5 times ULN~* Lactic dehydrogenase \< 5 times ULN~Renal~* BUN \< 1.5 times ULN~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No uncontrolled angina pectoris~* No myocardial infarction within the past 6 months~* No uncontrolled high blood pressure~* No evolutive intracranial hypertension~* No other severe cardiac disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active gastroduodenal ulcer~* No diabetes~* No active or uncontrolled infection~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~* No other uncontrolled severe medical condition~* No other malignancy within the past 5 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunologic or biologic therapy~Chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for metastatic disease~* No concurrent radiotherapy~Surgery~* Recovered from prior major surgery~Other~* No prior antineoplastic drugs for metastatic disease~* More than 4 weeks since prior investigational drugs~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).